# Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors

Source: https://onco.cc/trials/nct06144671/  
OnCo record `nct06144671` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GT201 in advanced solid tumours, run by Grit Biotechnology, now recruiting.

## Summary

Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06144671 by Grit Biotechnology, with 78 participants planned, started 2025-11-01 and due to reach its primary completion in 2027-12-30. Interventions recorded: GT201, IL-2 and PD-1 inhibitor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06144671
- Phase: 1/2
- Setting: Phase I/II Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT201 Injection) as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
- Sponsor: Grit Biotechnology
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT06144671: https://clinicaltrials.gov/study/NCT06144671

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06144671.json